Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Secukinumab
Other

Secukinumab

Tracked across 1 events · 6 articles · First seen May 31, 2026 · Last active Jun 01, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 60
Tech
Novartis presents positive immunology data
Novartis presented new data from 31 abstracts across its immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress in London from June 3-6, 2026. Key presentations included new data for Secukinumab>>> (secukinumab)…
Impact: Secukinumab (secukinumab) is a key drug in Novartis's immunology portfolio, with new positive data from the REPLENISH Phase III trial in polymyalgia rheumatica being presented. This could expand its market and increase sales.
May 31, 2026 · 6 articles
Key Actions (1)
90 Novartis highlighted data SecukinumabNovartis presents positive...
NEWSDESK
Track Secukinumab live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.